PDT Partners LLC Buys 65,378 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)

PDT Partners LLC grew its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) by 30.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 280,382 shares of the company’s stock after purchasing an additional 65,378 shares during the quarter. PDT Partners LLC’s holdings in Adaptive Biotechnologies were worth $1,436,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ADPT. Rubric Capital Management LP grew its stake in shares of Adaptive Biotechnologies by 2.9% during the third quarter. Rubric Capital Management LP now owns 14,400,000 shares of the company’s stock valued at $73,728,000 after buying an additional 400,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Adaptive Biotechnologies by 0.8% during the first quarter. Vanguard Group Inc. now owns 12,869,818 shares of the company’s stock valued at $41,312,000 after acquiring an additional 102,134 shares during the last quarter. ARK Investment Management LLC boosted its holdings in shares of Adaptive Biotechnologies by 1.7% during the third quarter. ARK Investment Management LLC now owns 11,601,134 shares of the company’s stock worth $59,398,000 after purchasing an additional 189,134 shares during the period. Millennium Management LLC grew its stake in shares of Adaptive Biotechnologies by 1,008.3% in the second quarter. Millennium Management LLC now owns 9,262,341 shares of the company’s stock worth $33,530,000 after purchasing an additional 8,426,580 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in Adaptive Biotechnologies by 12.1% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 7,733,884 shares of the company’s stock valued at $39,597,000 after purchasing an additional 834,253 shares during the period. 99.17% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. BTIG Research increased their price objective on Adaptive Biotechnologies from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Piper Sandler lifted their price target on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an “overweight” rating in a report on Monday, November 11th.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $5.94 on Monday. The company has a 50-day simple moving average of $5.07 and a two-hundred day simple moving average of $4.39. The firm has a market capitalization of $876.63 million, a PE ratio of -4.43 and a beta of 1.45. Adaptive Biotechnologies Co. has a one year low of $2.28 and a one year high of $6.70.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.